Literature DB >> 21378031

Platelet activating factor: the good and the bad in the ischemic/reperfused heart.

Claudia Penna1, Eleonora Bassino, Giuseppe Alloatti.   

Abstract

The present review is focused on the dual role played by platelet-activating factor (PAF) in ischemia and reperfusion (I/R) injury of the heart. Although the involvement of PAF in the pathogenesis of myocardial reperfusion injury is well established, in the last few years it has emerged that very low concentrations of PAF exert cardioprotective effects, comparable to that afforded by ischemic preconditioning (IP). PAF is a potent phosphoglyceride involved in different pathophysiological conditions affecting the cardiovascular system, including the development of myocardial I/R injury. PAF is released from the I/R myocardium in concentrations (1-10 nmol/L) high enough to negatively modulate coronary circulation as well as electrical and contractile activities. PAF may act either directly, via generation of secondary mediators, or through the activation of inflammatory cells like platelets and polymorphonuclear neutrophils, which exacerbate postischemic myocardial injury. The effects of PAF are mediated through specific receptors (PAFRs) that belong to the superfamily of G protein-coupled receptors. Since cardiomyocytes not only produce PAF but also possess PAFRs, it is likely that PAF acts as an autocrine/paracrine mediator. Although the negative effects exerted by high concentrations of PAF are well established, several recent findings from our and other laboratories have demonstrated that very low concentrations (pmol/L) of PAF infused before ischemia induce cardioprotective effects similar to those afforded by IP, and that endogenous PAF production participates in the induction of IP itself. The IP-like action exerted by low concentrations of PAF is due to the activation/phosphorylation of kinases included in the reperfusion injury salvage kinase (RISK) pathway, such as protein kinase C, Akt/PkB and nitric oxide synthase. Together with the activation of mitochondrial K(ATP) channels, these events may allow prevention of mitochondrial permeability transition pores opening at reperfusion. Moreover, the nitric oxide-dependent S-nitrosylation of L-type Ca(2+) channels induced by PAF reduces intracellular Ca(2+) overload.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378031     DOI: 10.1258/ebm.2011.010316

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  15 in total

Review 1.  High-density lipoprotein and atherosclerosis: the role of antioxidant activity.

Authors:  Salman Bandeali; John Farmer
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

2.  Platelet-activating factor stimulates sodium-hydrogen exchange in ventricular myocytes.

Authors:  Yoichi Ajiro; Noriko Saegusa; Wayne R Giles; Diana M Stafforini; Kenneth W Spitzer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-23       Impact factor: 4.733

3.  Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case control study: a case-control study.

Authors:  Guo-Hua Zheng; Shang-Quan Xiong; Li-Juan Mei; Hai-Ying Chen; Ting Wang; Jian-Feng Chu
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

Review 4.  A review of experimental evidence linking neurotoxic organophosphorus compounds and inflammation.

Authors:  Christopher N Banks; Pamela J Lein
Journal:  Neurotoxicology       Date:  2012-02-10       Impact factor: 4.294

Review 5.  The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection.

Authors:  Derek J Hausenloy; William Chilian; Filippo Crea; Sean M Davidson; Peter Ferdinandy; David Garcia-Dorado; Niels van Royen; Rainer Schulz; Gerd Heusch
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787

Review 6.  Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Christina Chrysohoou; Smaragdi Antonopoulou
Journal:  Curr Heart Fail Rep       Date:  2013-06

7.  Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling.

Authors:  Maria-Giulia Perrelli; Francesca Tullio; Carmelina Angotti; Maria Carmela Cerra; Tommaso Angelone; Bruno Tota; Giuseppe Alloatti; Claudia Penna; Pasquale Pagliaro
Journal:  Pflugers Arch       Date:  2013-01-15       Impact factor: 3.657

Review 8.  Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future.

Authors:  Michael V Cohen; James M Downey
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 9.  Redox signalling and cardioprotection: translatability and mechanism.

Authors:  P Pagliaro; C Penna
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 10.  Circulating blood cells and extracellular vesicles in acute cardioprotection.

Authors:  Sean M Davidson; Ioanna Andreadou; Lucio Barile; Yochai Birnbaum; Hector A Cabrera-Fuentes; Michael V Cohen; James M Downey; Henrique Girao; Pasquale Pagliaro; Claudia Penna; John Pernow; Klaus T Preissner; Péter Ferdinandy
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.